Group 1 - Labcorp Holdings reported revenue of $3.52 billion for the quarter ended December 2025, reflecting a 5.6% increase year-over-year [1] - The company's EPS for the quarter was $4.07, up from $3.45 in the same quarter last year, with an EPS surprise of +2.98% compared to the consensus estimate of $3.95 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $3.55 billion, resulting in a revenue surprise of -0.97% [1] Group 2 - Key metrics indicate that Labcorp's shares have returned +4.3% over the past month, outperforming the Zacks S&P 500 composite, which declined by -1.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Group 3 - The net book-to-bill ratio for Labcorp was reported at 1.1%, matching the average estimate based on two analysts [4] - Revenues from Biopharma Laboratory Services were $793 million, slightly above the average estimate of $791.05 million, representing a year-over-year change of +3.4% [4] - Revenues from Diagnostics Laboratories were $2.73 billion, below the average estimate of $2.77 billion, with a year-over-year change of +5.5% [4] - Adjusted Operating Income for Diagnostics Laboratories was $419.2 million, slightly below the average estimate of $423.58 million [4] - Adjusted Operating Income for Biopharma Laboratory Services was $136.1 million, exceeding the average estimate of $130.1 million [4] - Unallocated corporate expenses were reported at -$67.6 million, better than the average estimate of -$69.13 million [4]

Fourth Quarter 2025 Supplemental Financial Information February 17, 2026 labcorp Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 auidance and related assumations. (li) the impact of various factors on operating and financial results. including alobal economic and market conditions on the company's businesses, operating results, cash flows and/or financial conditio ...

Core Insights - Labcorp Holdings (LH) reported $3.56 billion in revenue for Q3 2025, marking an 8.6% year-over-year increase and an EPS of $4.18 compared to $3.50 a year ago [1] - The reported revenue aligns with the Zacks Consensus Estimate of $3.56 billion, resulting in a slight surprise of -0.01%, while the EPS exceeded the consensus estimate of $4.13 by 1.21% [1] Financial Performance Metrics - The net book-to-bill ratio was reported at 1.1%, slightly below the two-analyst average estimate of 1.2% [4] - Revenue from Biopharma Laboratory Services reached $799.1 million, surpassing the average estimate of $793.17 million, reflecting an 8.3% year-over-year increase [4] - Revenue from Diagnostics Laboratories was $2.77 billion, matching the average estimate and showing an 8.5% year-over-year growth [4] - Adjusted Operating Income for Diagnostics Laboratories was $450.4 million, exceeding the average estimate of $444.52 million [4] - Adjusted Operating Income for Biopharma Laboratory Services was $132.2 million, slightly above the average estimate of $130.39 million [4] - Unallocated corporate expenses were reported at -$69.3 million, worse than the average estimate of -$66.07 million [4] Stock Performance - Labcorp's shares have returned -2.5% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Insights - Labcorp Holdings Inc. is positioned for growth due to the robust performance of its Biopharma Laboratory Services segment and a strong focus on operational efficiency [1][3][5] - The company has experienced a 24.1% stock increase over the past year, outperforming the industry and the S&P 500 [2] - Despite strong financial health and operational initiatives, macroeconomic challenges may limit Labcorp's growth potential [1][9] Financial Performance - Labcorp has a market capitalization of $23.04 billion and an earnings yield of 5.8%, surpassing the industry's 4.2% [2] - The company reported a 11% year-over-year growth in its Biopharma Laboratory Services segment in Q2 2025, with Central Laboratories growing by 8% and Early Development by 20% [3][8] - The Zacks Consensus Estimate for Labcorp's 2025 earnings remains at $16.30, with revenues expected to reach $14.00 billion, indicating a 7.7% increase from 2024 [10] Operational Efficiency - Labcorp is enhancing operational efficiency through initiatives like LaunchPad, which improved the adjusted operating margin by 20 basis points in Q2 [5][6] - The introduction of digital solutions such as the Labcorp Diagnostic Assistant and eClaim Assist aims to streamline workflows and improve billing efficiencies [6] Financial Health - As of Q2 2025, Labcorp had cash and cash equivalents of $793 million, short-term debt of $500 million, and long-term debt of $5.08 billion [7] - The company returned capital to shareholders through $59.9 million in dividends and $200 million in stock repurchases, with a dividend payout ratio of 19% [7] Challenges - Macroeconomic factors, including inflation and geopolitical tensions, have negatively impacted demand for diagnostic testing and drug development services, leading to an 8.1% increase in the cost of revenues year-over-year [9]

Core Viewpoint - Labcorp Holdings (LH) is expected to report quarterly earnings of $4.14 per share, reflecting a 5.1% increase year-over-year, with revenues projected at $3.49 billion, an 8.3% increase from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Biopharma Laboratory Services' at $743.20 million, a 5.1% increase from the prior-year quarter [5]. - The average estimate for 'Revenues- Diagnostics Laboratories' is $2.74 billion, reflecting an 8.7% increase year-over-year [5]. Operating Income Estimates - 'Adjusted Operating Income- Biopharma Laboratory Services' is projected to reach $117.62 million, up from $107.40 million in the same quarter last year [6]. - 'Adjusted Operating Income- Diagnostics Laboratories' is expected to be $466.41 million, compared to $441.50 million a year ago [6]. Stock Performance - Labcorp shares have returned -6.9% over the past month, contrasting with the Zacks S&P 500 composite's +5.4% change [6]. - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6].

Core Insights - Labcorp reported revenue of $3.35 billion for the quarter ended March 2025, reflecting a year-over-year increase of 5.3% [1] - The company's EPS was $3.84, up from $3.68 in the same quarter last year, exceeding the consensus estimate of $3.73 by 2.95% [1] - The revenue fell short of the Zacks Consensus Estimate of $3.41 billion, resulting in a surprise of -2.04% [1] Financial Performance Metrics - The net book-to-bill ratio was reported at 1.1%, surpassing the estimated 1% by analysts [4] - Revenue from Biopharma Laboratory Services was $721.30 million, below the average estimate of $742.69 million, but showing a year-over-year increase of 1.5% [4] - Revenue from Diagnostics Laboratories was $2.63 billion, compared to the average estimate of $2.69 billion, with a year-over-year increase of 6.1% [4] - Adjusted Operating Income for Biopharma Laboratory Services was $106.90 million, slightly below the estimated $108.86 million [4] - Adjusted Operating Income for Diagnostics Laboratories was $427.50 million, compared to the average estimate of $435.69 million [4] Stock Performance - Labcorp's shares have returned -1.4% over the past month, while the Zacks S&P 500 composite has changed by -0.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]